Nox’s Acquisition of Somryst a ‘Major Milestone’
Nox Health recently agreed to pay $3.9 million to acquire the prescription digital therapeutic for chronic insomnia from Pear Therapeutics in its bankruptcy auction.
Nox Health recently agreed to pay $3.9 million to acquire the prescription digital therapeutic for chronic insomnia from Pear Therapeutics in its bankruptcy auction.
Teach patients these relaxation exercises as part of their insomnia therapy.
Pear Therapeutics is exploring strategic alternatives—including acquisition, sale, or merger—to maximize shareholder value.
Vanda’s trial results of HETLIOZ (tasimelteon) for insomnia suggest that circadian misalignment may be the etiology behind chronic primary insomnia for many patients.
In clinical studies, DAYVIGO helped some people with insomnia fall asleep faster and stay asleep longer compared to placebo.
Geriatric populations are simultaneously more likely to have insomnia and less likely to tell their medical team about it.
The prevalence, possible etiological mechanisms, and suggested treatment order of comorbid insomnia and obstructive sleep apnea, as explained by a researcher on the team that coined the term ‘COMISA.’